Firstline Sequential AG and mFOLFOX Combined With Serplulimab and Bevacizumab Versus AG Chemotherapy Alone in Advanced Pancreatic Cancer

A randomized, multicenter, Phase III trial evaluating the efficacy and safety of first-line Sequential AG-mFOLFOX chemotherapy combined with Serplulimab and Bevacizumab versus AG chemotherapy alone in advanced pancreatic cancer. The primary endpoint is Overall Survival (OS). Approximately 292 patients will be enrolled in China.

Trial Details

NCT ID
NCT07235930
Phase
PHASE3
Sponsor
Zhejiang Cancer Hospital
Status
RECRUITING
Cancer Type
Pancreatic Cancer
Interventions
  • Sequential AG and mFOLFOX in Combination With Serplulimab and Bevacizumab
  • AG chemotherapy
Locations (sample)
  • Hangzhou, Zhejiang, China|30.29365,120.16142

Key Eligibility Criteria

  • Voluntarily agree to participate in the study and sign the informed consent;
  • ≥18 years of age and ≤75 years of age on the day of signing the informed consent form, regardless of gender;
  • Pancreatic ductal adenocarcinoma confirmed by pathologic histology or cytology;
  • No prior systemic therapy for unresectable locally advanced or metastatic pancreatic cancer;

For full eligibility, visit ClinicalTrials.gov.

Check If You May Be Eligible

Trialify translates complex eligibility criteria into plain yes-or-no questions to help you understand if this trial might be right for you.

Find Pancreatic Cancer Trials on Trialify →